Molecule

Image: iStock/Pilin_Petunyia

AstraZeneca sets out on a $1bn 'Bicycle' path

By Dan Stanton

AstraZeneca has partnered with Bicycle Therapeutics in a potential $1bn deal to develop a new class of small molecules which have antibody-like properties.

The new FormPrep platform automates biologic formulation preparation. (iStock:

Unchained Labs continues breaking into biologics market

By Melissa Fassbender

Unchained Labs has acquired Freeslate, a provider of high-throughput solutions for biologics formulation development and small molecule chemistry – marking the company’s 4th acquisition in 12 months.